LY6G6F-LY6G6D

Across TCGA pan-cancer cohorts, LY6G6F-LY6G6D RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of LY6G6F-LY6G6D’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where LY6G6F-LY6G6D RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LY6G6F-LY6G6D is over-expressed in tumor, although a few such as BLCA and LUAD show the opposite, repressed pattern.

COAD, BLCA, and LUAD are the cancer types where LY6G6F-LY6G6D tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LY6G6F-LY6G6D RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	All	+3.098	<.001	12	view →
BLCA	Female	All	−0.347	<.001	11	view →
LUAD	Female	All	−0.069	<.001	7	view →
THCA	Male	All	−0.209	<.001	5	view →
HNSC	Female	III,IV	−0.286	.004	3	view →
KIRC	All	II,III,IV	−0.006	.012	3	view →
PRAD	All	All	−0.738	<.001	2	view →
READ	All	All	+1.788	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

LY6G6F-LY6G6D–COAD

Open the COAD breakdown →